The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Evolve From 2026 To 2030?

The market size for ornithine transcarbamylase deficiency (otc deficiency) has experienced robust growth in recent years. It is projected to expand from $0.89 billion in 2025 to $0.95 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this growth can be attributed to several factors, including limited treatment options and a high disease burden, increasing awareness of otc deficiency in neonates, early adoption of liver transplant and dietary management, a surge in research for rare genetic disorders, and the rising prevalence of hyperammonemia-related complications.

The market for ornithine transcarbamylase deficiency (OTC deficiency) is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $1.23 billion, demonstrating a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period stems from factors such as an expanding array of gene and mRNA-based therapies, greater access to enzyme replacement and protein engineering solutions, an increase in the use of precision medicine, heightened investments in research for rare diseases, and the broadening of diagnostic testing and genetic screening initiatives. Key developments expected during this timeframe involve a surge in the adoption of gene therapy for OTC deficiency, a stronger emphasis on individualized and targeted treatment strategies, increased public understanding of early diagnosis via genetic testing, a growing need for enzyme replacement and protein engineering treatments, and a heightened clinical focus on monitoring and managing ammonia levels.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp

What Major Drivers Are Influencing Demand In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

The market for ornithine transcarbamylase deficiency is anticipated to expand, fueled by the increasing demand for gene therapies. Gene therapy is defined as a medical approach involving the modification or manipulation of an individual’s genetic material to either treat existing diseases or prevent their occurrence. This growing demand for gene therapies stems from the increasing incidence of genetic disorders, which frequently lack effective treatment options; gene therapy presents a hopeful method for tackling the underlying cause of these conditions instead of merely alleviating symptoms. Ornithine transcarbamylase deficiency serves as an illustration of gene therapies’ potential, as it can rectify the genetic mutation responsible for disrupting the urea cycle, enabling precise treatment aimed at restoring metabolic function and preventing the buildup of toxic ammonia. As an example, the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, reported in January 2024 that the quantity of gene therapies in Phase III trials saw a 10% increase in Q4 2023 compared to the prior quarter, marking the first such rise since Q3 2022. Consequently, the increasing need for gene therapies is propelling the expansion of the ornithine transcarbamylase deficiency market.

Which Segment Areas Are Covered In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Analysis?

The ornithine transcarbamylase deficiency (otc deficiency) market covered in this report is segmented –

1) By Product Type: DTX-301, SEL-313, SHP-641, PRX-OTC

2) By Treatment Type: Gene Therapy, Liver Transplant, Dietary Management, Other Treatement Types

3) By Diagnosis: Genetic Testing, Ammonia Level Testing

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy, Intravenous Dosing Formulation

2) By SEL-313: Immune Tolerance-Inducing Therapy, Enzyme Replacement Therapy (ERT) Combination

3) By SHP-641: Small Molecule Therapy, mRNA-Based Therapeutic Approach

4) By PRX-OTC: Recombinant Enzyme Replacement Therapy, Protein Engineering-Based Therapy

Which Market Trends Are Creating New Opportunities In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Companies prominent in the ornithine transcarbamylase deficiency (OTC Deficiency) market are concentrating on developing novel treatments, such as mRNA therapeutics, to boost treatment effectiveness and address the fundamental genetic origin of OTC deficiency. mRNA therapeutics constitute a category of treatments that employ messenger RNA (mRNA) to direct cells to create specific proteins for therapeutic goals. These therapies capitalize on the body’s innate protein synthesis processes to treat conditions including genetic disorders, infectious diseases, and cancers. For instance, in June 2023, Arcturus Therapeutics Holdings Inc., a US-based biotechnology company, obtained Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency. This designation seeks to hasten the drug’s development and evaluation process, potentially offering advantages like more frequent FDA interactions and a priority review. ARCT-810 is formulated to enable patients with OTC deficiency, a urea cycle disorder, to generate functional OTC enzyme in their liver cells, thereby resolving the underlying cause of the condition and possibly enhancing their quality of life.

Which Global Companies Are Actively Competing In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Major companies operating in the ornithine transcarbamylase deficiency (otc deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.

Read the full ornithine transcarbamylase deficiency (otc deficiency) market report here:

https://www.thebusinessresearchcompany.com/report/ornithine-transcarbamylase-deficiency-otc-deficiency-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (otc deficiency) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22084&type=smp

Browse Through More Reports Similar to the Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market 2026, By The Business Research Company

Oryzanol Global Market Report

https://www.thebusinessresearchcompany.com/report/oryzanol-global-market-report

Orthobiologics Global Market Report

https://www.thebusinessresearchcompany.com/report/orthobiologics-global-market-report

Auditing Services Global Market Report

https://www.thebusinessresearchcompany.com/report/auditing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model